Tag Archives: cardiovascular-renal-metabolic (CVRM)

ACEi/ARB use Despite overwhelming evidence and innumerable local, regional, national and international guidelines, the prescription of ACEi/ARB therapies for patients with CKD have remained (to use Dr Hostetter’s word) ‘woeful’. North American data showed that between 1999 and 2014 the use of ACEi/ARB therapy in patients with CKD rose from 25.5% between 1999 and 2002 to 40.1% between 2011 and 2014, with their use being the exception unless patients had additional diseases, such as diabetes mellitus or cardiac disease.6 These findings are consistent with National Health and Nutrition Examination Survey data, which suggested that only 39